Adc Therapeutics SA
Q2 2026 Earnings
Market Reaction
S&P 500 over the same 30 days: −2.63%.
Did ADCT Beat Earnings? Q2 2026 Results
ADC Therapeutics delivered a notably cleaner quarter than Wall Street had anticipated, posting an adjusted loss of $0.11 per share in Q2 2026, beating the consensus estimate of $0.22 by 49.07%, while revenue of $19.25 million edged past expectations of $18.90 million and grew 2.2% year-over-year. The headline improvement was driven primarily by a 29% reduction in total operating expenses, including a 17% workforce reduction expected to generate roughly $10 million in annualized savings, which helped narrow the GAAP net loss to $16.57 million from $56.65 million in the year-ago period. The brighter financials, however, are shadowed by a significant regulatory setback: the FDA raised serious concerns about the benefit-risk profile of LOTIS-5, citing a pronounced imbalance in fatal adverse events despite the trial meeting its primary endpoint. Against that headwind, the company pointed to a 78% complete response rate in its LOTIS-7 combination trial as a potential path forward, with Breakthrough Therapy designation submissions planned and revenue growth anticipated starting in 2027, supported by a cash runway extending into at least 2028.
- ZYNLONTA product revenue increase driven by higher price
- Total operating expenses reduced 29% year-over-year due to lower R&D spending on discontinued programs
- Net loss favorably impacted by change in fair value of warrants and cumulative catch-up adjustment of deferred royalty obligation
- 17% workforce reduction generating ~$10 million annualized cost savings
“We are pleased by our second quarter performance, which reflects continued commercial momentum and strong operational discipline through ongoing cost reduction efforts. Over the course of this year, we have released LOTIS-5 data and completed the LOTIS-7 trial. With these data now in hand, we believe that ZYNLONTA plus glofitamab offers an opportunity to take a leading second-line plus position, in the context of the evolving competitive landscape, solidifying ZYNLONTA as a foundational therapy in DLBCL.”
ADC Therapeutics CEO, on the earnings call
Forward Guidance & Outlook
ADC Therapeutics anticipates revenue growth starting in 2027, driven by potential compendia inclusion for ZYNLONTA. The company is evaluating the best regulatory path forward following FDA concerns about LOTIS-5 benefit-risk profile, and plans to provide a regulatory strategy update in the near future. The company is assessing a Phase 3 trial for ZYNLONTA plus glofitamab based on LOTIS-7 data and plans to submit for Breakthrough Therapy designation for both the LOTIS-7 combination and MZL indication. Updated FL IIT data are expected in Q2 2027. The company expects a cash runway into at least 2028. The recently announced 17% workforce reduction is expected to generate annualized cost savings of approximately $10 million.
ADCT YoY Financials
ADCT Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.